🇺🇸 FDA
Pipeline program

recombinant adenovirus containing the ornithine transcarbamylase gene

199/12054

Phase 1 gene_therapy terminated

Quick answer

recombinant adenovirus containing the ornithine transcarbamylase gene for Ornithine Transcarbamylase Deficiency Disease is a Phase 1 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Ornithine Transcarbamylase Deficiency Disease
Phase
Phase 1
Modality
gene_therapy
Status
terminated

Clinical trials